| Outcome Measures: |
Primary: Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks, To see if Dapagliflozin reduces LV mass more than placebo in participants with type 2 diabetes and LV hypertrophy, Baseline and 52 weeks | Secondary: Change in 24 hour blood pressure (BP) recording at 52 weeks, To confirm expected effect of dapagliflozin on BP, Baseline and 52 weeks|Change in Office blood pressure (BP) at 4, 17, 34 and 52 weeks, To confirm expected effect of dapagliflozin on BP, Baseline, 4, 17, 34 and 52 weeks|Change in Body mass index at 4, 17, 34 and 52 weeks, To confirm expected effect of dapagliflozin on body mass index, Baseline 4, 17, 34 and 52 weeks|Change in waist/hip ratio at 4, 17, 34 and 52 weeks, To confirm expected effect of dapagliflozin on waist/hip ratio, Baseline 4, 17, 34 and 52 weeks|Change in waist circumference at 4, 17, 34 and 52 weeks, To confirm expected effect of dapagliflozin on waist circumference, Baseline 4, 17, 34 and 52 weeks|Change in visceral fat massed with Abdominal MRI at 52 weeks, To assess the effect of dapagliflozin on visceral fat mass., Baseline and 52 weeks|Change in HbA1c at 4, 17, 34 and 52 weeks, To assess the effects of dapagliflozin on HbA1c, Baseline, 4, 17, 34 and 52 weeks|Number of patients with adverse events related to treatment, Urinary symptoms and hypotensive symptoms will assess the tolerability of dapagliflozin in this patient group, 4, 17, 34 and 52 weeks|Number of participants with abnormal laboratory values, Liver function tests will assess the tolerability of dapagliflozin in this patient group, 4, 17, 34 and 52 weeks|Change in Fasting Insulin Resistance Index (FIRI) at 4, 17, 34 and 52 weeks, To assess the effects of dapagliflozin on FIRI, Baseline, 4, 17, 34 and 52 weeks|Change in B-type Natriuretic Peptide (BNP) at 4, 17, 34 and 52 weeks, To assess the effects of dapagliflozin on BNP, Baseline, 4, 17, 34 and 52 weeks|Change in uric acid at 4, 17, 34 and 52 weeks, To assess the effects of dapagliflozin on uric acid, Baseline, 4, 17, 34 and 52 weeks|Change in diastolic function and global longitudinal strain, To assess the effect of dapagliflozin on left ventricular diastolic function, Baseline and 52 weeks
|
